GlassScriptPhysician profile
Ali M Sarram
NPI 1043213929
$75,753.19
in general payments reported to CMS, 2019-2025
38 companies · $3,598 in 2025
The $3,598 reported for 2025 was more than what 88% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,505 · 2020: $718 · 2021: $19K · 2022: $18K · 2023: $11K · 2024: $23K · 2025: $3,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Food and Beverage: $3,256 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $330 · Travel and Lodging: $93.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,639.00 |
| Food and Beverage | $3,256.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $330.00 |
| Travel and Lodging | $93.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $35,491.46 | 2021-2025 | Urolift, Barrigel |
| Procept Biorobotics Corporation | $35,220.51 | 2019-2025 | Aquabeam System, Aquabeam Robotic System |
| Ferring Pharmaceuticals INC. | $1,155.69 | 2019-2024 | Adstiladrin, Firmagon |
| Boston Scientific Corporation | $628.39 | 2019-2025 | Axonics, Spaceoar Vue System - 10ml, General - Kidney Stone Disease |
| Covidien LP | $625.00 | 2020 | |
| Astellas Pharma US INC | $521.48 | 2019-2025 | Xtandi |
| Olympus America INC. | $254.95 | 2022-2025 | Itind System |
| Abbvie INC. | $231.04 | 2022-2025 | Botox |
| Janssen Biotech, INC. | $149.28 | 2025 | Erleada |
| Allergan, INC. | $109.38 | 2019-2021 | |
| Pfizer INC. | $100.93 | 2023-2025 | |
| Comsort, INC | $100.00 | 2019 | |
| Axonics, INC. | $99.73 | 2022-2024 | Bulkamid, Axonics |
| Sumitomo Pharma America, INC. | $97.87 | 2023-2025 | Gemtesa, Orgovyx |
| Tolmar, INC. | $94.14 | 2024-2025 | Eligard, Jatenzo |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Sarram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.